[SCHEDULE 13G/A] Allogene Therapeutics, Inc. SEC Filing
Allogene Therapeutics' Schedule 13G/A shows that David D. Chang, M.D., Ph.D., and related family trusts report combined beneficial ownership of 11,136,728 shares of common stock, representing 5.0% of the class. The filing states that this total includes 5,413,414 shares issuable upon exercise of options exercisable within 60 days, and breaks out voting and dispositive power as 8,223,532 shares sole and 2,913,196 shares shared. Separate trusts鈥攖he Chang 2006 Family Trust, JEC 2019 Trust and RTC 2019 Trust鈥攔eport holdings of 1,201,108, 856,044 and 856,044 shares respectively, representing 0.5% and two 0.4% stakes. The percentage is calculated using 218,730,809 shares outstanding as disclosed by the issuer.
La Schedule 13G/A di Allogene Therapeutics indica che David D. Chang, M.D., Ph.D., e trust familiari correlati dichiarano una titolarit脿 beneficiaria combinata di 11.136.728 azioni ordinarie, pari al 5,0% della classe. Il deposito specifica che tale totale comprende 5.413.414 azioni emesse mediante l鈥檈sercizio di opzioni esercitabili entro 60 giorni, e ripartisce il potere di voto e di disposizione in 8.223.532 azioni in via esclusiva e 2.913.196 azioni in condivisione. Trust separati 鈥� Chang 2006 Family Trust, JEC 2019 Trust e RTC 2019 Trust 鈥� riportano partecipazioni di 1.201.108, 856.044 e 856.044 azioni rispettivamente, corrispondenti allo 0,5% e a due quote dello 0,4%. La percentuale 猫 calcolata sulla base di 218.730.809 azioni in circolazione come dichiarato dall鈥檈mittente.
El Schedule 13G/A de Allogene Therapeutics muestra que David D. Chang, M.D., Ph.D., y fideicomisos familiares relacionados declaran una titularidad beneficiaria combinada de 11.136.728 acciones ordinarias, lo que representa el 5,0% de la clase. La presentaci贸n indica que este total incluye 5.413.414 acciones emitibles por ejercicio de opciones ejercitables dentro de 60 d铆as, y desglosa el poder de voto y de disposici贸n como 8.223.532 acciones en exclusiva y 2.913.196 acciones compartidas. Fideicomisos separados鈥擟hang 2006 Family Trust, JEC 2019 Trust y RTC 2019 Trust鈥攔eportan tenencias de 1.201.108, 856.044 y 856.044 acciones respectivamente, representando 0,5% y dos participaciones de 0,4%. El porcentaje se calcula usando 218.730.809 acciones en circulaci贸n seg煤n lo declarado por el emisor.
Allogene Therapeutics鞚� Schedule 13G/A鞐� 霐半ゴ氅� David D. Chang, M.D., Ph.D.鞕� 甏�霠� 臧�臁� 鞁犿儊霌れ潃 頃╈偘 鞁れ 靻岇湢甓岇溂搿� 氤错喌欤� 11,136,728欤�毳� 氤搓碃頄堨溂氅�, 鞚措姅 頃措嫻 韥措灅鞀れ潣 5.0%鞐� 頃措嫻頃╇媹雼�. 靹滊電� 鞚� 齑濎垬鞐� 60鞚� 鞚措偞 頄夓偓 臧�電ロ暅 鞓奠厴鞚� 韱淀暣 氚滍枆 臧�電ロ暅 5,413,414欤�臧� 韽暔霅滊嫟瓿� 氚濏瀳瓿�, 鞚橁舶甓� 氚� 觳橂秳甓岇潉 8,223,532欤� 雼弲瓿� 2,913,196欤� 瓿惦彊鞙茧 甑秳頃╇媹雼�. 氤勲弰鞚� 鞁犿儊霌�(Chang 2006 Family Trust, JEC 2019 Trust, RTC 2019 Trust)鞚� 臧侁皝 1,201,108欤�, 856,044欤�, 856,044欤�毳� 氤挫湢頃橁碃 鞛堨柎 0.5%鞕� 0.4%鞌╈潣 歆�攵� 霊� 瓯挫潉 雮橅儉雰呺媹雼�. 鞚� 牍勳湪鞚� 氚滍枆靷皜 瓿奠嫓頃� 218,730,809欤�鞚� 鞙犿喌欤检嫕靾橂ゼ 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�.
Le Schedule 13G/A d'Allogene Therapeutics indique que David D. Chang, M.D., Ph.D., et des trusts familiaux apparent茅s d茅clarent une propri茅t茅 b茅n茅ficiaire combin茅e de 11 136 728 actions ordinaires, repr茅sentant 5,0% de la cat茅gorie. Le d茅p么t pr茅cise que ce total comprend 5 413 414 actions susceptibles d'锚tre 茅mises 脿 l'exercice d'options exer莽ables dans les 60 jours, et ventile le pouvoir de vote et de disposition en 8 223 532 actions en pleine propri茅t茅 et 2 913 196 actions en propri茅t茅 partag茅e. Des trusts distincts 鈥� Chang 2006 Family Trust, JEC 2019 Trust et RTC 2019 Trust 鈥� d茅clarent des participations de 1 201 108, 856 044 et 856 044 actions respectivement, repr茅sentant 0,5% et deux participations de 0,4%. Le pourcentage est calcul茅 sur la base de 218 730 809 actions en circulation telles que divulgu茅es par l'茅metteur.
Die Schedule 13G/A von Allogene Therapeutics weist aus, dass David D. Chang, M.D., Ph.D., und zugeh枚rige Familientrusts eine kombinierte wirtschaftliche Beteiligung von 11.136.728 Aktien des Stammkapitals melden, was 5,0% der Klasse entspricht. Die Einreichung gibt an, dass diese Summe 5.413.414 Aktien umfasst, die bei Aus眉bung von Optionen binnen 60 Tagen ausgegeben werden k枚nnen, und gliedert Stimm- und Verf眉gungsrechte in 8.223.532 Aktien ausschlie脽lich und 2.913.196 Aktien gemeinsam. Separate Trusts 鈥� Chang 2006 Family Trust, JEC 2019 Trust und RTC 2019 Trust 鈥� melden Best盲nde von 1.201.108, 856.044 und 856.044 Aktien, die 0,5% bzw. zwei Beteiligungen zu je 0,4% repr盲sentieren. Die Prozentangabe basiert auf 218.730.809 ausstehenden Aktien, wie vom Emittenten angegeben.
- Aggregate beneficial ownership disclosed at 11,136,728 shares, equal to 5.0% of the outstanding class
- Includes 5,413,414 options exercisable within 60 days, aligning insider economic interests with shareholders
- Concentration of voting power with 8,223,532 shares held with sole voting power
- Significant portion of the position is option-based, which may change ownership dynamics if exercised
Insights
TL;DR: Insider ownership totals 5.0%, including large option positions exercisable soon, indicating meaningful insider economic exposure but not a control change.
The filing discloses a 5.0% aggregate stake (11,136,728 shares) held by Dr. Chang and affiliated trusts, of which ~48.6% (5,413,414 shares) are option-based and exercisable within 60 days. Sole voting power exceeds shared power, showing where voting influence resides. For valuation or liquidity analysis, the option component can dilute or shift timing of economic exposure and should be modeled explicitly. Overall, this is a material disclosure of insider alignment but lacks signs of an activist or control intent.
TL;DR: Beneficial ownership by a single executive above 5% triggers governance attention but the filing shows routine disclosure, not overt control or a group action.
The report identifies Dr. Chang as beneficial owner and co-trustee of three trusts holding combined positions. The mix of sole (8,223,532) and shared (2,913,196) voting power is relevant for board engagement and vote planning. The filing indicates no group formation or additional parties; Itemized disclosures (e.g., trusts, option exercise within 60 days) enable clear assessment of who can direct votes. No immediate governance red flags are presented, though stakeholders should note concentration and option-driven potential shifts in ownership.
La Schedule 13G/A di Allogene Therapeutics indica che David D. Chang, M.D., Ph.D., e trust familiari correlati dichiarano una titolarit脿 beneficiaria combinata di 11.136.728 azioni ordinarie, pari al 5,0% della classe. Il deposito specifica che tale totale comprende 5.413.414 azioni emesse mediante l鈥檈sercizio di opzioni esercitabili entro 60 giorni, e ripartisce il potere di voto e di disposizione in 8.223.532 azioni in via esclusiva e 2.913.196 azioni in condivisione. Trust separati 鈥� Chang 2006 Family Trust, JEC 2019 Trust e RTC 2019 Trust 鈥� riportano partecipazioni di 1.201.108, 856.044 e 856.044 azioni rispettivamente, corrispondenti allo 0,5% e a due quote dello 0,4%. La percentuale 猫 calcolata sulla base di 218.730.809 azioni in circolazione come dichiarato dall鈥檈mittente.
El Schedule 13G/A de Allogene Therapeutics muestra que David D. Chang, M.D., Ph.D., y fideicomisos familiares relacionados declaran una titularidad beneficiaria combinada de 11.136.728 acciones ordinarias, lo que representa el 5,0% de la clase. La presentaci贸n indica que este total incluye 5.413.414 acciones emitibles por ejercicio de opciones ejercitables dentro de 60 d铆as, y desglosa el poder de voto y de disposici贸n como 8.223.532 acciones en exclusiva y 2.913.196 acciones compartidas. Fideicomisos separados鈥擟hang 2006 Family Trust, JEC 2019 Trust y RTC 2019 Trust鈥攔eportan tenencias de 1.201.108, 856.044 y 856.044 acciones respectivamente, representando 0,5% y dos participaciones de 0,4%. El porcentaje se calcula usando 218.730.809 acciones en circulaci贸n seg煤n lo declarado por el emisor.
Allogene Therapeutics鞚� Schedule 13G/A鞐� 霐半ゴ氅� David D. Chang, M.D., Ph.D.鞕� 甏�霠� 臧�臁� 鞁犿儊霌れ潃 頃╈偘 鞁れ 靻岇湢甓岇溂搿� 氤错喌欤� 11,136,728欤�毳� 氤搓碃頄堨溂氅�, 鞚措姅 頃措嫻 韥措灅鞀れ潣 5.0%鞐� 頃措嫻頃╇媹雼�. 靹滊電� 鞚� 齑濎垬鞐� 60鞚� 鞚措偞 頄夓偓 臧�電ロ暅 鞓奠厴鞚� 韱淀暣 氚滍枆 臧�電ロ暅 5,413,414欤�臧� 韽暔霅滊嫟瓿� 氚濏瀳瓿�, 鞚橁舶甓� 氚� 觳橂秳甓岇潉 8,223,532欤� 雼弲瓿� 2,913,196欤� 瓿惦彊鞙茧 甑秳頃╇媹雼�. 氤勲弰鞚� 鞁犿儊霌�(Chang 2006 Family Trust, JEC 2019 Trust, RTC 2019 Trust)鞚� 臧侁皝 1,201,108欤�, 856,044欤�, 856,044欤�毳� 氤挫湢頃橁碃 鞛堨柎 0.5%鞕� 0.4%鞌╈潣 歆�攵� 霊� 瓯挫潉 雮橅儉雰呺媹雼�. 鞚� 牍勳湪鞚� 氚滍枆靷皜 瓿奠嫓頃� 218,730,809欤�鞚� 鞙犿喌欤检嫕靾橂ゼ 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�.
Le Schedule 13G/A d'Allogene Therapeutics indique que David D. Chang, M.D., Ph.D., et des trusts familiaux apparent茅s d茅clarent une propri茅t茅 b茅n茅ficiaire combin茅e de 11 136 728 actions ordinaires, repr茅sentant 5,0% de la cat茅gorie. Le d茅p么t pr茅cise que ce total comprend 5 413 414 actions susceptibles d'锚tre 茅mises 脿 l'exercice d'options exer莽ables dans les 60 jours, et ventile le pouvoir de vote et de disposition en 8 223 532 actions en pleine propri茅t茅 et 2 913 196 actions en propri茅t茅 partag茅e. Des trusts distincts 鈥� Chang 2006 Family Trust, JEC 2019 Trust et RTC 2019 Trust 鈥� d茅clarent des participations de 1 201 108, 856 044 et 856 044 actions respectivement, repr茅sentant 0,5% et deux participations de 0,4%. Le pourcentage est calcul茅 sur la base de 218 730 809 actions en circulation telles que divulgu茅es par l'茅metteur.
Die Schedule 13G/A von Allogene Therapeutics weist aus, dass David D. Chang, M.D., Ph.D., und zugeh枚rige Familientrusts eine kombinierte wirtschaftliche Beteiligung von 11.136.728 Aktien des Stammkapitals melden, was 5,0% der Klasse entspricht. Die Einreichung gibt an, dass diese Summe 5.413.414 Aktien umfasst, die bei Aus眉bung von Optionen binnen 60 Tagen ausgegeben werden k枚nnen, und gliedert Stimm- und Verf眉gungsrechte in 8.223.532 Aktien ausschlie脽lich und 2.913.196 Aktien gemeinsam. Separate Trusts 鈥� Chang 2006 Family Trust, JEC 2019 Trust und RTC 2019 Trust 鈥� melden Best盲nde von 1.201.108, 856.044 und 856.044 Aktien, die 0,5% bzw. zwei Beteiligungen zu je 0,4% repr盲sentieren. Die Prozentangabe basiert auf 218.730.809 ausstehenden Aktien, wie vom Emittenten angegeben.
FAQ
How many ALLO shares does David D. Chang beneficially own?
Does the reported ownership include exercisable options for ALLO?
What voting power does Dr. Chang hold in ALLO?
Which trusts are reported and how many ALLO shares do they own?
On what share base is the percentage ownership calculated for ALLO?
